<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE root>
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="research-article" dtd-version="1.2" xml:lang="en"><front><journal-meta><journal-id journal-id-type="publisher-id">Current Alzheimer Research</journal-id><journal-title-group><journal-title xml:lang="en">Current Alzheimer Research</journal-title><trans-title-group xml:lang="ru"><trans-title>Current Alzheimer Research</trans-title></trans-title-group></journal-title-group><issn publication-format="print">1567-2050</issn><issn publication-format="electronic">1875-5828</issn></journal-meta><article-meta><article-id pub-id-type="publisher-id">643715</article-id><article-id pub-id-type="doi">10.2174/0115672050295561240327055835</article-id><article-categories><subj-group subj-group-type="toc-heading"><subject>Medicine</subject></subj-group><subj-group subj-group-type="article-type"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title xml:lang="en">Evaluation and Characterization of Modified K114 Method to Localize Plaques in Rodent and Plaques and Tangles in Human Brain Tissue</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Padala</surname><given-names>Sanjana</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Setti</surname><given-names>Sharay</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Raymick</surname><given-names>James</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib><contrib contrib-type="author"><name><surname>Hanig</surname><given-names>Joseph</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff2"/></contrib><contrib contrib-type="author"><name><surname>Sarkar</surname><given-names>Sumit</given-names></name><email>info@benthamscience.net</email><xref ref-type="aff" rid="aff1"/></contrib></contrib-group><aff id="aff1"><institution>Division of Neurotoxicology, National Center for Toxicological Research, U.S. Food &amp; Drug Administration</institution></aff><aff id="aff2"><institution>Office of Testing &amp; Research, Center for Drug Evaluation Research/FDA</institution></aff><pub-date date-type="pub" iso-8601-date="2024-01-01" publication-format="electronic"><day>01</day><month>01</month><year>2024</year></pub-date><volume>21</volume><issue>1</issue><fpage>69</fpage><lpage>80</lpage><history><date date-type="received" iso-8601-date="2025-01-07"><day>07</day><month>01</month><year>2025</year></date></history><permissions><copyright-statement xml:lang="en">Copyright ©; 2024, Bentham Science Publishers</copyright-statement><copyright-year>2024</copyright-year><copyright-holder xml:lang="en">Bentham Science Publishers</copyright-holder><ali:free_to_read xmlns:ali="http://www.niso.org/schemas/ali/1.0/"/></permissions><self-uri xlink:href="https://journals.eco-vector.com/1567-2050/article/view/643715">https://journals.eco-vector.com/1567-2050/article/view/643715</self-uri><abstract xml:lang="en"><p id="idm46041443776176">Background:A plethora of studies has shown the utility of several chemical dyes due to their affinity to bind Aβ to enable visualization of plaques under light or fluorescence microscope, and some of them showed affinity to bind neurofibrillary tangles (NFT) as well. However, only a few of them have the propensity to bind both senile plaques (SP) and NFT simultaneously.</p><p id="idm46041443780176">Objective:In our current study, we aimed to modify the K114 dye and the staining procedure to substantially improve the staining of amyloid plaques in both human and rodent brains and neurofibrillary tangles in the human brain</p><p id="idm46041443784144">Methods:We modified the K114 solution and the staining procedure using Sudan Black as a modifier. Additionally, to evaluate the target of the modified K114, we performed double labeling of K114 and increased Aβ against three different epitopes. We used 5 different antibodies to detect phosphorylated tau to understand the specific targets that modified K114 binds.</p><p id="idm46041443789200">method:We have modified the K114 solution and the staining procedure using Sudan Black as modifier. Additionally, to evaluate the target of the modified K114, we performed double labeling of K114, and Aβ raised against three different epitopes. We used 5 different antibodies to detect phosphorylated Tau to understand the potential binding targets.</p><p id="idm46041443798576">Results:Dual labeling using hyperphosphorylated antibodies against AT8, pTau, and TNT1 revealed that more than 80% hyperphosphorylated tau colocalized with tangles that were positive for modified K114, whereas more than 70% of the hyperphosphorylated tau colocalized with modified K114. On the other hand, more than 80% of the plaques that were stained with Aβ MOAB-2 were colocalized with modified K114.</p><p id="idm46041443806224">result:We have found more than 80% hyperphosphorylated Tau against AT8, PTau and TNT1 colocalized with K114 labeled tangles, whereas more than 70% of the hyperphosphorylated Tau colocalized with modified K114. On the other hand, more than 80% of the plaques that were stained with amyloid beta MOAB-2 were colocalized with modified K114.</p><p id="idm46041443814144">Conclusion:Our modified method can label amyloid plaques within 5 min in the rat brain and within 20 min in the human brain. Our results indicated that modified K114 could be used as a valuable tool for detecting amyloid plaques and tangles with high contrast and resolution relative to other conventional fluorescence markers.</p></abstract><kwd-group xml:lang="en"><kwd>Amyloid beta</kwd><kwd>plaques</kwd><kwd>neurofibrillary tangles</kwd><kwd>histochemical tracer</kwd><kwd>styrylbenzene</kwd><kwd>Alzheimer&amp;amp</kwd><kwd>rsquo</kwd><kwd>s disease</kwd><kwd>phosphorylated tau.</kwd></kwd-group></article-meta></front><body></body><back><ref-list><ref id="B1"><label>1.</label><mixed-citation>2023 Alzheimers disease facts and figures. Alzheimers Dement., 2023, 19(4), 1598-1695. doi: 10.1002/alz.13016 PMID: 36918389</mixed-citation></ref><ref id="B2"><label>2.</label><mixed-citation>Hardy, J.; Allsop, D. Amyloid deposition as the central event in the aetiology of Alzheimers disease. Trends Pharmacol. Sci., 1991, 12(10), 383-388. doi: 10.1016/0165-6147(91)90609-V PMID: 1763432</mixed-citation></ref><ref id="B3"><label>3.</label><mixed-citation>Hardy, J.; Selkoe, D.J. The amyloid hypothesis of Alzheimers disease: Progress and problems on the road to therapeutics. Science, 2002, 297(5580), 353-356. doi: 10.1126/science.1072994 PMID: 12130773</mixed-citation></ref><ref id="B4"><label>4.</label><mixed-citation>Hardy, J.A.; Higgins, G.A. Alzheimers disease: The amyloid cascade hypothesis. Science, 1992, 256(5054), 184-185. doi: 10.1126/science.1566067 PMID: 1566067</mixed-citation></ref><ref id="B5"><label>5.</label><mixed-citation>Alonso, A.C.; Grundke-Iqbal, I.; Barra, H.S.; Iqbal, K. Abnormal phosphorylation of tau and the mechanism of Alzheimer neurofibrillary degeneration: Sequestration of microtubule-associated proteins 1 and 2 and the disassembly of microtubules by the abnormal tau. Proc. Natl. Acad. Sci. USA, 1997, 94(1), 298-303. doi: 10.1073/pnas.94.1.298 PMID: 8990203</mixed-citation></ref><ref id="B6"><label>6.</label><mixed-citation>Alonso, A.C.; Grundke-Iqbal, I.; Iqbal, K. Alzheimers disease hyperphosphorylated tau sequesters normal tau into tangles of filaments and disassembles microtubules. Nat. Med., 1996, 2(7), 783-787. doi: 10.1038/nm0796-783 PMID: 8673924</mixed-citation></ref><ref id="B7"><label>7.</label><mixed-citation>Alonso, A.; Li, B.; Grundke-Iqbal, I.; Iqbal, K. Mechanism of tau-induced neurodegeneration in Alzheimer disease and related tauopathies. Curr. Alzheimer Res., 2008, 5(4), 375-384. doi: 10.2174/156720508785132307 PMID: 18690834</mixed-citation></ref><ref id="B8"><label>8.</label><mixed-citation>Iqbal, K.; Alonso, A.C.; Grundke-Iqbal, I. Cytosolic abnormally hyperphosphorylated tau but not paired helical filaments sequester normal MAPs and inhibit microtubule assembly. J. Alzheimers Dis., 2008, 14(4), 365-370. doi: 10.3233/JAD-2008-14402 PMID: 18688085</mixed-citation></ref><ref id="B9"><label>9.</label><mixed-citation>Aghourian, M.; Aumont, É.; Grothe, M.J.; Soucy, J.P.; Rosa-Neto, P.; Bedard, M.A. FEOBV-PET to quantify cortical cholinergic denervation in AD: Relationship to basal forebrain volumetry. J. Neuroimaging, 2021, 31(6), 1077-1081. doi: 10.1111/jon.12921 PMID: 34462992</mixed-citation></ref><ref id="B10"><label>10.</label><mixed-citation>Aghourian, M.; Legault-Denis, C.; Soucy, J-P.; Rosa-Neto, P.; Gauthier, S.; Kostikov, A.; Gravel, P.; Bédard, M-A. Quantification of brain cholinergic denervation in Alzheimers disease using PET imaging with 18F-FEOBV. Mol. Psychiatry, 2017, 22(11), 1531-1538. doi: 10.1038/mp.2017.183 PMID: 28894304</mixed-citation></ref><ref id="B11"><label>11.</label><mixed-citation>Bedard, M.A.; Aghourian, M.; Legault-Denis, C.; Postuma, R.B.; Soucy, J.P.; Gagnon, J.F.; Pelletier, A.; Montplaisir, J. Brain cholinergic alterations in idiopathic REM sleep behaviour disorder: A PET imaging study with 18F-FEOBV. Sleep Med., 2019, 58, 35-41. doi: 10.1016/j.sleep.2018.12.020 PMID: 31078078</mixed-citation></ref><ref id="B12"><label>12.</label><mixed-citation>Nejad-Davarani, S.; Koeppe, R.A.; Albin, R.L.; Frey, K.A.; Müller, M.L.T.M.; Bohnen, N.I. Quantification of brain cholinergic denervation in dementia with Lewy bodies using PET imaging with 18F-FEOBV. Mol. Psychiatry, 2019, 24(3), 322-327. doi: 10.1038/s41380-018-0130-5 PMID: 30082840</mixed-citation></ref><ref id="B13"><label>13.</label><mixed-citation>de la Torre, J.; Aliev, G.; Perry, G. Drug therapy in Alzheimers disease. N. Engl. J. Med., 2004, 351(18), 1911-1913. doi: 10.1056/NEJM200410283511822 PMID: 15509830</mixed-citation></ref><ref id="B14"><label>14.</label><mixed-citation>de La Torre, J.C. Alzheimers disease is a vasocognopathy: A new term to describe its nature. Neurol. Res., 2004, 26(5), 517-524. doi: 10.1179/016164104225016254 PMID: 15265269</mixed-citation></ref><ref id="B15"><label>15.</label><mixed-citation>de la Torre, J.C. Is Alzheimers disease a neurodegenrative or vascular disorder? (vol 3, pg 184, 2004). Lancet Neurol., 2004, 3(5), 270-270. PMID: 15099540</mixed-citation></ref><ref id="B16"><label>16.</label><mixed-citation>Scheffer, S.; Hermkens, D.M.A.; van der Weerd, L.; de Vries, H.E.; Daemen, M.J.A.P. Vascular hypothesis of Alzheimer disease. Arterioscler. Thromb. Vasc. Biol., 2021, 41(4), 1265-1283. doi: 10.1161/ATVBAHA.120.311911 PMID: 33626911</mixed-citation></ref><ref id="B17"><label>17.</label><mixed-citation>Bourgade, K. Anti-viral properties of Amyloid-β Peptides., J Alzheimers Dis., 2016, 54(3), 859-878.</mixed-citation></ref><ref id="B18"><label>18.</label><mixed-citation>Bourgade, K.; Garneau, H.; Giroux, G.; Le Page, A.Y.; Bocti, C.; Dupuis, G.; Frost, E.H.; Fülöp, T., Jr β-Amyloid peptides display protective activity against the human Alzheimers disease-associated herpes simplex virus-1. Biogerontology, 2015, 16(1), 85-98. doi: 10.1007/s10522-014-9538-8 PMID: 25376108</mixed-citation></ref><ref id="B19"><label>19.</label><mixed-citation>Bourgade, K.; Le Page, A.; Bocti, C.; Witkowski, J.M.; Dupuis, G.; Frost, E.H.; Fülöp, T., Jr Protective effect of Amyloid-β Peptides against Herpes Simplex Virus-1 infection in a neuronal cell culture model. J. Alzheimers Dis., 2016, 50(4), 1227-1241. doi: 10.3233/JAD-150652 PMID: 26836158</mixed-citation></ref><ref id="B20"><label>20.</label><mixed-citation>Fulop, T.; Ramassamy, C.; Lévesque, S.; Frost, E.H.; Laurent, B.; Lacombe, G.; Khalil, A.; Larbi, A.; Hirokawa, K.; Desroches, M.; Rodrigues, S.; Bourgade, K.; Cohen, A.A.; Witkowski, J.M. Viruses - a major cause of amyloid deposition in the brain. Expert Rev. Neurother., 2023, 23(9), 775-790. doi: 10.1080/14737175.2023.2244162 PMID: 37551672</mixed-citation></ref><ref id="B21"><label>21.</label><mixed-citation>Fulop, T.; Witkowski, J.M.; Bourgade, K.; Khalil, A.; Zerif, E.; Larbi, A.; Hirokawa, K.; Pawelec, G.; Bocti, C.; Lacombe, G.; Dupuis, G.; Frost, E.H. Can an infection hypothesis explain the beta amyloid hypothesis of Alzheimers disease? Front. Aging Neurosci., 2018, 10, 224. doi: 10.3389/fnagi.2018.00224 PMID: 30087609</mixed-citation></ref><ref id="B22"><label>22.</label><mixed-citation>Akiyama, H.; Arai, T.; Kondo, H.; Tanno, E.; Haga, C.; Ikeda, K. Cell mediators of inflammation in the Alzheimer disease brain. Alzheimer Dis. Assoc. Disord., 2000, 14(Suppl.), S47-S53. doi: 10.1097/00002093-200000001-00008 PMID: 10850730</mixed-citation></ref><ref id="B23"><label>23.</label><mixed-citation>Akiyama, H.; Barger, S.; Barnum, S.; Bradt, B.; Bauer, J.; Cole, G.M.; Cooper, N.R.; Eikelenboom, P.; Emmerling, M.; Fiebich, B.L.; Finch, C.E.; Frautschy, S.; Griffin, W.S.; Hampel, H.; Hull, M.; Landreth, G.; Lue, L.; Mrak, R.; Mackenzie, I.R.; McGeer, P.L.; OBanion, M.K.; Pachter, J.; Pasinetti, G.; Plata-Salaman, C.; Rogers, J.; Rydel, R.; Shen, Y.; Streit, W.; Strohmeyer, R.; Tooyoma, I.; Van Muiswinkel, F.L.; Veerhuis, R.; Walker, D.; Webster, S.; Wegrzyniak, B.; Wenk, G.; Wyss-Coray, T. Inflammation and Alzheimers disease. Neurobiol. Aging, 2000, 21(3), 383-421. doi: 10.1016/S0197-4580(00)00124-X PMID: 10858586</mixed-citation></ref><ref id="B24"><label>24.</label><mixed-citation>Pillai, J.A.; Bena, J.; Bebek, G.; Bekris, L.M.; Bonner-Jackson, A.; Kou, L.; Pai, A.; Sørensen, L.; Neilsen, M.; Rao, S.M.; Chance, M.; Lamb, B.T.; Leverenz, J.B. Inflammatory pathway analytes predicting rapid cognitive decline in MCI stage of Alzheimers disease. Ann. Clin. Transl. Neurol., 2020, 7(7), 1225-1239. doi: 10.1002/acn3.51109 PMID: 32634865</mixed-citation></ref><ref id="B25"><label>25.</label><mixed-citation>Pillai, J.A.; Maxwell, S.; Bena, J.; Bekris, L.M.; Rao, S.M.; Chance, M.; Lamb, B.T.; Leverenz, J.B. Key inflammatory pathway activations in the MCI stage of Alzheimers disease. Ann. Clin. Transl. Neurol., 2019, 6(7), 1248-1262. doi: 10.1002/acn3.50827 PMID: 31353852</mixed-citation></ref><ref id="B26"><label>26.</label><mixed-citation>Cummings, J.; Aisen, P.; Lemere, C.; Atri, A.; Sabbagh, M.; Salloway, S. Aducanumab produced a clinically meaningful benefit in association with amyloid lowering. Alzheimers Res. Ther., 2021, 13(1), 98. doi: 10.1186/s13195-021-00838-z PMID: 33971962</mixed-citation></ref><ref id="B27"><label>27.</label><mixed-citation>Padala, S.P.; Yarns, B.C. Under-represented populations left out of alzheimers disease treatment with aducanumab: Commentary on ethics. J. Alzheimers Dis. Rep., 2022, 6(1), 345-348. doi: 10.3233/ADR-220023 PMID: 35891635</mixed-citation></ref><ref id="B28"><label>28.</label><mixed-citation>Stepanchuk, A.A.; Heyne, B.; Stys, P.K. Complex photophysical properties of k114 make for a versatile fluorescent probe for amyloid detection. ACS Chem. Neurosci., 2021, 12(7), 1273-1280. doi: 10.1021/acschemneuro.1c00101 PMID: 33705095</mixed-citation></ref><ref id="B29"><label>29.</label><mixed-citation>Setti, S.E.; Raymick, J.; Hanig, J.; Sarkar, S. In vivo demonstration of Congo Red labeled amyloid plaques via perfusion in the Alzheimer disease rat model. J. Neurosci. Methods, 2021, 353, 109082. doi: 10.1016/j.jneumeth.2021.109082 PMID: 33508413</mixed-citation></ref><ref id="B30"><label>30.</label><mixed-citation>Iadanza, M.G.; Jackson, M.P.; Hewitt, E.W.; Ranson, N.A.; Radford, S.E. A new era for understanding amyloid structures and disease. Nat. Rev. Mol. Cell Biol., 2018, 19(12), 755-773. doi: 10.1038/s41580-018-0060-8 PMID: 30237470</mixed-citation></ref><ref id="B31"><label>31.</label><mixed-citation>Selmani, V.; Robbins, K.J.; Ivancic, V.A.; Lazo, N.D. K114 ( trans, trans )-bromo-2,5-bis(4-hydroxystyryl)benzene is an efficient detector of cationic amyloid fibrils. Protein Sci., 2015, 24(3), 420-425. doi: 10.1002/pro.2620 PMID: 25524064</mixed-citation></ref><ref id="B32"><label>32.</label><mixed-citation>LeVine, H., III Mechanism of Aβ(1−40) Fibril-Induced Fluorescence of ( trans, trans )-1-Bromo-2,5-bis(4-hydroxystyryl)benzene (K114). Biochemistry, 2005, 44(48), 15937-15943. doi: 10.1021/bi051252l PMID: 16313197</mixed-citation></ref><ref id="B33"><label>33.</label><mixed-citation>Crystal, A.S.; Giasson, B.I.; Crowe, A.; Kung, M.P.; Zhuang, Z.P.; Trojanowski, J.Q.; Lee, V.M.Y. A comparison of amyloid fibrillogenesis using the novel fluorescent compound K114. J. Neurochem., 2003, 86(6), 1359-1368. doi: 10.1046/j.1471-4159.2003.01949.x PMID: 12950445</mixed-citation></ref><ref id="B34"><label>34.</label><mixed-citation>Stepanchuk, A.A.; Barber, P.A.; Lashley, T.; Joseph, J.T.; Stys, P.K. Quantitative detection of grey and white matter amyloid pathology using a combination of K114 and CRANAD-3 fluorescence. Neurobiol. Dis., 2021, 161, 105540. doi: 10.1016/j.nbd.2021.105540 PMID: 34751140</mixed-citation></ref><ref id="B35"><label>35.</label><mixed-citation>Elghetany, M.T.; Saleem, A. Methods for staining amyloid in tissues: A review. Stain Technol., 1988, 63(4), 201-212. doi: 10.3109/10520298809107185 PMID: 2464206</mixed-citation></ref><ref id="B36"><label>36.</label><mixed-citation>Glenner, G.G.; Eanes, E.D.; Page, D.L. The relation of the properties of Congo red-stained amyloid fibrils to the -conformation. J. Histochem. Cytochem., 1972, 20(10), 821-826. doi: 10.1177/20.10.821 PMID: 4638557</mixed-citation></ref><ref id="B37"><label>37.</label><mixed-citation>Styren, S.D.; Hamilton, R.L.; Styren, G.C.; Klunk, W.E. X-34, a fluorescent derivative of Congo red: A novel histochemical stain for Alzheimers disease pathology. J. Histochem. Cytochem., 2000, 48(9), 1223-1232. doi: 10.1177/002215540004800906 PMID: 10950879</mixed-citation></ref><ref id="B38"><label>38.</label><mixed-citation>Skovronsky, D.M.; Zhang, B.; Kung, M.P.; Kung, H.F.; Trojanowski, J.Q.; Lee, V.M.Y. In vivo detection of amyloid plaques in a mouse model of Alzheimers disease. Proc. Natl. Acad. Sci. USA, 2000, 97(13), 7609-7614. doi: 10.1073/pnas.97.13.7609 PMID: 10861023</mixed-citation></ref><ref id="B39"><label>39.</label><mixed-citation>Schmidt, M.L.; Schuck, T.; Sheridan, S.; Kung, M.P.; Kung, H.; Zhuang, Z.P.; Bergeron, C.; Lamarche, J.S.; Skovronsky, D.; Giasson, B.I.; Lee, V.M.Y.; Trojanowski, J.Q. The fluorescent Congo red derivative, (trans, trans)-1-bromo-2,5-bis-(3-hydroxycarbonyl-4-hydroxy)styrylbenzene (BSB), labels diverse β-pleated sheet structures in postmortem human neurodegenerative disease brains. Am. J. Pathol., 2001, 159(3), 937-943. doi: 10.1016/S0002-9440(10)61769-5 PMID: 11549586</mixed-citation></ref><ref id="B40"><label>40.</label><mixed-citation>Setti, S.E.; Das, N.; Raymick, J.; Hanig, J.; Sarkar, S. Evaluation of Styrylbenzene analog- FSB and its affinity to bind parenchymal plaques and tangles in patients of Alzheimers disease. Metab. Brain Dis., 2022, 37(3), 639-651. doi: 10.1007/s11011-021-00885-3 PMID: 35064472</mixed-citation></ref><ref id="B41"><label>41.</label><mixed-citation>Puchtler, H.; Sweat, F. Congo red as a stain for fluorescence microscopy of amyloid. J. Histochem. Cytochem., 1965, 13(8), 693-694. doi: 10.1177/13.8.693 PMID: 4160077</mixed-citation></ref><ref id="B42"><label>42.</label><mixed-citation>Kelényi, G. Thioflavin S fluorescent and Congo red anisotropic stainings in the histologic demonstration of amyloid. Acta Neuropathol., 1967, 7(4), 336-348. doi: 10.1007/BF00688089 PMID: 4166287</mixed-citation></ref><ref id="B43"><label>43.</label><mixed-citation>Schmued, L.; Raymick, J.; Tolleson, W.; Sarkar, S.; Zhang, Y.H.; Bell-Cohn, A. Introducing Amylo-Glo, a novel fluorescent amyloid specific histochemical tracer especially suited for multiple labeling and large scale quantification studies. J. Neurosci. Methods, 2012, 209(1), 120-126. doi: 10.1016/j.jneumeth.2012.05.019 PMID: 22705750</mixed-citation></ref><ref id="B44"><label>44.</label><mixed-citation>Åslund, A.; Sigurdson, C.J.; Klingstedt, T.; Grathwohl, S.; Bolmont, T.; Dickstein, D.L.; Glimsdal, E.; Prokop, S.; Lindgren, M.; Konradsson, P.; Holtzman, D.M.; Hof, P.R.; Heppner, F.L.; Gandy, S.; Jucker, M.; Aguzzi, A.; Hammarström, P.; Nilsson, K.P.R. Novel pentameric thiophene derivatives for in vitro and in vivo optical imaging of a plethora of protein aggregates in cerebral amyloidoses. ACS Chem. Biol., 2009, 4(8), 673-684. doi: 10.1021/cb900112v PMID: 19624097</mixed-citation></ref><ref id="B45"><label>45.</label><mixed-citation>Sigurdson, C.J.; Nilsson, K.P.R.; Hornemann, S.; Manco, G.; Polymenidou, M.; Schwarz, P.; Leclerc, M.; Hammarström, P.; Wüthrich, K.; Aguzzi, A. Prion strain discrimination using luminescent conjugated polymers. Nat. Methods, 2007, 4(12), 1023-1030. doi: 10.1038/nmeth1131 PMID: 18026110</mixed-citation></ref></ref-list></back></article>
